Diagnostic and Prognostic Value of High‐Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.041680 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Milagros Pereyra Pietri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Troponin T, Cardiovascular Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Immune‐checkpoint inhibitors (ICI) are associated with adverse cardiac events. Although troponin elevation is a diagnostic criterion for ICI‐related myocarditis (ICIrM) and myocardial infarction, data on other causes of troponin elevation and their outcomes in ICI‐treated patients are limited.
Methods
All patients treated with ICI who had hs‐TnT (high‐sensitivity troponin T) measured at a multicenter institution from 2011 to 2022 were included. Clinical data, outcomes (cardiac death, heart failure (HF), major adverse cardiovascular events [myocardial infarction, stroke, heart failure]), and cause of hs‐TnT elevation were assessed. Risks of cardiac events were compared across hs‐TnT elevation causes.
Results
Of 5423 patients treated with ICI, 1669 had post‐ICI hs‐TnT measurement (mean age 68.7±11.3 years, 58.3% male), with 1‐year follow‐up. Hs‐TnT elevation in patients with ICIrM (n=59) was associated with the highest risk for cardiac death (hazard ratio [HR], 52.7 [95% CI, 11.7–238.0], P 319 ng/L for major adverse cardiovascular events.
Conclusions
Hs‐TnT elevation after ICI therapy is associated with increased risk of cardiac events, particularly in ICIrM, and a graded prognostic association depending on the cause of hs‐TnT elevation. Identifying the underlying cause and troponin thresholds may guide risk stratification and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA.
- Department of Cardiovascular Medicine Mayo Clinic Rochester MN USA.
ORCID-Profile: Milagros Pereyra Pietri, Christopher N Kanaan, Courtney R Kenyon, Ahmed K Mahmoud, Mohammed Tiseer Abbas, Nima Baba Ali, Hema Narayanasamy, Kwan S Lee, Reza Arsanjani, Chadi Ayoub
Zitieren
APA
Pereyra Pietri, M., Farina, J. M., Awad, K., Kanaan, C. N., Scalia, I. G., Tagle-Cornell, C., Novais, B. S., Koepke, L. M., Kenyon, C. R., Mahmoud, A. K., Abbas, M. T., Ali, N. B., Larsen, C. M., Narayanasamy, H., Tamarappoo, B., Lee, K. S., Herrmann, J., Arsanjani, R., & Ayoub, C. (2026). Diagnostic and Prognostic Value of High‐Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041680
Vancouver
Pereyra Pietri M, Farina JM, Awad K, Kanaan CN, Scalia IG, Tagle-Cornell C, et al. Diagnostic and Prognostic Value of High‐Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.041680
BibTeX
@article{PereyraPietri2026,
author = {Pereyra Pietri, Milagros and Farina, Juan M and Awad, Kamal and Kanaan, Christopher N and Scalia, Isabel G and Tagle-Cornell, Cecilia and Novais, Barbara S and Koepke, Laura M and Kenyon, Courtney R and Mahmoud, Ahmed K and Abbas, Mohammed Tiseer and Ali, Nima Baba and Larsen, Carolyn M and Narayanasamy, Hema and Tamarappoo, Balaji and Lee, Kwan S and Herrmann, Joerg and Arsanjani, Reza and Ayoub, Chadi},
title = {Diagnostic and Prognostic Value of High‐Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.041680}
}
EUVIMED